Precision Financing Solutions for Durable / Potentially Curative Therapies

Eric NormanFoCUS, Whitepapers

The NEWDIGS FoCUS consortium of multiple stakeholders (payers, providers, patient advocacy organizations, pharmaceutical developers, academics and others) has been working collaboratively since 2016 to address the need for new, innovative … Read More

Incorporation of Value-Based Payment Agreements into the Calculation of Medicaid Drug Rebates

Eric NormanFoCUS, Research Briefs

Value-Based Payment (VBP) agreements will play an important role in mitigating uncertainty in durable therapies, where it is unclear whether a large upfront payment is justified based on limited clinical … Read More

Model Contracts for Innovative Oncology Therapies

Eric NormanFoCUS, Research Briefs

When there is substantial uncertainty about a new product’s expected value, stakeholders may have strong reasons to consider performance-based contracts. One of the hardest tasks in crafting such contracts is … Read More

Designing financial solutions to ensure affordable access to cures

Eric NormanFoCUS, Whitepapers

The reimbursement of emerging durable/potentially curative cell and gene therapies is likely to be a challenge for the US healthcare market. Considering the pricing of cell- and gene-based therapies approved … Read More

Stop-Loss Insurance or Reinsurance for Multiyear Contracts

Eric NormanFoCUS, Research Briefs

In previous Research Briefs, we have discussed challenges faced by payers when contemplating using multiyear performance-based contracts. In this brief, we extend the discussion to include additional difficulties that may … Read More